RE: Analytical sensitivity in today’s RNS23 Nov 2020 18:55
CO,
I am wondering just what AVACTA is exposing their Lateral Flow test to:
* Is it just spike proteins, without the rest of the viral particle? Is just spike proteins possible? I can see that just spike proteins might be safer than whole viral particles.
Thinking about the conversion factors between the units:
* If a viral particle had a mass of 10^-15 g, including all its spike proteins, then I am thinking that the mass of a single spike protein must be much, much, less than 10^-15 g.
* The previous bullet point might suggest millions(?) of viral particles per ml for Avacta.
But the reasoning may be wrong!!
If Avacta is say >300,000 viral particles per ml, then sensitivity will be better than Innova. That's good enough reason until tender closure results for me!!
Recall Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance.
https://www.medrxiv.org/content/10.1101/2020.06.22.20136309v3
and the Harvard presentation:
https://m.youtube.com/watch?v=h7Sv_pS8MgQ
So apparently a sensitivity of 50% is acceptable for mass testing!
Well knowing this and knowing that Avacta's sensitivity should be empirically better than the Innova LFT has told me to add to my investment in Avacta today!
Test, test, test